RIGL Overview

Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.

Wall Street analysts forecast RIGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RIGL is52.00 USD with a low forecast of 38.00 USD and a high forecast of 71.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Rigel Pharmaceuticals Inc revenue for the last quarter amounts to 58.82M USD, increased 10.28

Rigel Pharmaceuticals Inc. EPS for the last quarter amounts to 0.44 USD, decreased -30.16

Rigel Pharmaceuticals Inc (RIGL) has 172 emplpoyees as of May 12 2026.

Today RIGL has the market capitalization of 484.75M USD.